Niraparib in ovarian cancer: results to date and clinical potential.

about

Niraparib in ovarian cancer: results to date and clinical potential.

Item

http://www.wikidata.org/entity/Q42820765

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Niraparib in ovarian cancer: results to date and clinical potential.

@en

Niraparib in ovarian cancer: results to date and clinical potential.

@nl

type

Item

label

Niraparib in ovarian cancer: results to date and clinical potential.

@en

Niraparib in ovarian cancer: results to date and clinical potential.

@nl

prefLabel

Niraparib in ovarian cancer: results to date and clinical potential.

@en

Niraparib in ovarian cancer: results to date and clinical potential.

@nl

P1476

Niraparib in ovarian cancer: results to date and clinical potential

@en

P2093

Anselmo Papa

http://www.w3.org/2001/XMLSchema#string

Davide Caruso

http://www.w3.org/2001/XMLSchema#string

Federica Tomao

http://www.w3.org/2001/XMLSchema#string

Pierluigi Benedetti Panici

http://www.w3.org/2001/XMLSchema#string

Silverio Tomao

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA-damage response in human biology and disease

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Integrated genomic analyses of ovarian carcinoma

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Unraveling the mechanism of BRCA2 in homologous recombination

PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase

Hallmarks of 'BRCAness' in sporadic cancers

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

P304

579-588

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834017718775

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Patrizia Vici

P577

2017-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29081841

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5564880

http://www.w3.org/2001/XMLSchema#string